Latest Alerts: Landstar System Inc. (NASDAQ:LSTR), Tuniu Corporation (NASDAQ:TOUR), American Shared Hospital Services (NYSEMKT:AMS), VIVUS Inc. (NASDAQ:VVUS), Sage Therapeutics (NASDAQ:SAGE)


Landstar System Inc. (NASDAQ:LSTR) shares advanced 0.69% in last trading session and ended the day at $66.87. LSTR Gross Margin is 14.90% and its has a return on assets of 14.90%. Landstar System Inc. (NASDAQ:LSTR) quarterly performance is 2.36%.

Landstar System, Inc. (Landstar) is an asset-light provider of integrated transportation management solutions. The Company offers services to its customers across multiple transportation modes, with the ability to arrange for individual shipments of freight to enterprise solutions to manage all of a customer’s transportation needs.

Landstar System, Inc. (NASDAQ:LSTR), a worldwide, asset-light provider of integrated transportation management solutions delivering safe, specialized transportation services, announced it will provide a live webcast of its mid-quarter conference call for its 2015 third quarter on Thursday, September 3rd at 4:00 pm ET.

Tuniu Corporation is an online travel company. The Company offers a selection of packaged tours, including organized tours, self-guided tours and travel-related services for leisure travelers. Its online platform, which consists of its tuniu.com Website and mobile platform, provides product and travel information to enable leisure travelers to plan their travels.

Tuniu Corporation (NASDAQ:TOUR) shares increased 11.14% in last trading session and ended the day at $12.67. TOUR Gross Margin is 5.60% and its has a return on assets of -27.20%. Tuniu Corporation (NASDAQ:TOUR) quarterly performance is -24.09%.

Tuniu Corp. (NASDAQ:TOUR) reported a loss of $39.7 million in its second quarter. The Nanjing, China-based company said it had a loss of 52 cents per share. Losses, adjusted for stock option expense and amortization costs, were 49 cents per share.

On 27 August, American Shared Hospital Services (NYSEMKT:AMS) shares moved down -1.80% and was closed at $2.18. AMS EPS growth in last 5 year was -36.60%. American Shared Hospital Services (NYSEMKT:AMS) year to date (YTD) performance is -22.42%.

American Shared Hospital Services (ASHS) along with its subsidiaries provides Gamma Knife stereotactic radiosurgery equipment and radiation therapy, and related equipment to approximately 17 medical centers in the United States and two medical centers in Turkey.

On 19 August, American Shared Hospital Services (NYSEMKT:AMS) reported medical services revenue increased 30.0% to $4,394,000 compared to medical services revenue of $3,379,000 for the second quarter of 2014. Revenue for last year’s second quarter included the Company’s operations in Turkey, which were sold effective May 31, 2014. Excluding prior year’s revenue in Turkey, medical services revenue increased 38.2% for the second quarter of 2015 compared to the second quarter of 2014.

VIVUS Inc. (NASDAQ:VVUS) shares moved down -0.89% in last trading session and ended the day at $1.11. VVUS Gross Margin is 67.00% and its has a return on assets of -29.80%. VIVUS Inc. (NASDAQ:VVUS) quarterly performance is -56.13%.

On August 17, 2015, VIVUS, Inc., (NASDAQ:VVUS) or the Company, and Svai S. Sanford entered into a letter agreement, or the Letter Agreement, in connection with Mr. Sanford’s voluntary termination of his employment with the Company and the Company’s desire to retain Mr. Sanford during the transition period. Under the Letter Agreement, the Company and Mr. Sanford agreed that Mr. Sanford’s employment as Chief Financial Officer and Chief Accounting Officer of the Company will terminate on September 30, 2015.

VIVUS, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products. It provides two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

Sage Therapeutics, Inc. (NASDAQ:SAGE) caters to the Healthcare space. Its weekly performance is -2.88%. On the last day of trading company shares ended up $52.92. Sage Therapeutics, Inc. (NASDAQ:SAGE) distance from 50-day simple moving average (SMA50) is -22.15%.

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening, rare central nervous system (CNS) disorders.

On 17 August, SAGE Therapeutics (NASDAQ:SAGE) announced it has treated the first patient enrolled in the STATUS Trial (SAGE-547 Treatment as Adjunctive Therapy Utilized in Status Epilepticus), a global, Phase 3, randomized, double-blind, placebo-controlled clinical trial to evaluate SAGE-547 as a treatment for patients with super-refractory status epilepticus (SRSE). SRSE is a rare, life-threatening condition of persistent, unremitting seizure, for which there are no approved therapies.


Leave a Reply

Your email address will not be published. Required fields are marked *